Drug Database
ES

estrogen (Estratab / esterified estrogen / Menest)

✓ Approved

AbbVie, Inc. · ESR1

What is estrogen?

estrogen is a therapeutic agent developed by AbbVie, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesEstratab, esterified estrogen, Menest
CompanyAbbVie, Inc.
Molecular TargetESR1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

estrogen acts on 1 molecular target:

ESR1estrogen receptor 1 (ER, ESR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

estrogen is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresHormone replacement therapy✓ Approved

Related Research Articles

PubMediScience2026-08-30

Single-nuclei RNA sequencing reveals obesity-associated rewiring of estrogen signaling in endometrioid adenocarcinoma.

Long Jessica L JL, Agrusa Sophia S, Pukhrambam Swornalata S, Ganesh Sanjeev S et al.

Endometrioid adenocarcinoma has one of the strongest body mass index associations of any solid tumor. This is widely attributed to amplification of estrogen-driven signaling via increased production of unopposed estrogen in peripheral adipose tissue. However, there is little evidence as to whether this is a pure dosage effect or if persistent signaling leads to feedback on the execution of that signaling. Using single-nucleus RNA sequencing of primary tumors from postmenopausal patients with normal and obese body mass indices, we identified coordinated transcriptional remodeling across tumor epithelial, immune, and stromal compartments. Network-level analysis of tumor epithelial cells revealed that ESR1-associated co-expression modules in tumors from patients with obesity were distinct across two independent patient cohorts and transcriptomic modalities. These network constructions were then shown to be enriched for estrogen receptor targets using existing chromatin immunoprecipitation data from endometrioid adenocarcinoma cell lines and normal endometrial tissue, as well as RNA-seq following exogenous exposure to estrogen for the cell lines. Thus, this study provides a single-nuclei atlas of endometrioid adenocarcinoma and suggests that obesity likely both amplifies estrogenic signaling and qualitatively reshapes its regulatory context.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

WTAP Transcriptional Suppression by KLF9 Drives Osteoclastogenesis via M6A-Mediated Regulation of CSF1R Signaling in Estrogen-Deficient Osteoporosis.

Shen Chen C, Liu Xin X, Ge Gaoran G, Xu Li L et al.

Osteoporosis, characterized by imbalanced bone homeostasis, is driven by excessive osteoclast-mediated bone resorption, yet the epitranscriptomic regulation via m6A modification remains unclear. Here, we identify WTAP, a component of the m6A methyltransferase complex, as a critical negative regulator of osteoclastogenesis. Myeloid-specific Wtap knockout in mice exacerbates osteoclast formation and osteoporotic bone loss. Mechanistically, WTAP mediates m6A deposition on Csflr mRNA, promoting degradation via the key m6A reader YTHDF2 and downregulating CSF1R expression, thereby enhancing osteoclastogenesis and bone loss in estrogen-deficient osteoporosis. We further discover that KLF9, induced during osteoclast differentiation, translocates to the nucleus to directly repress Wtap transcription, initiating this pathological process. Concurrent conditional knockout of KLF9 in osteoclast precursors rescues the exacerbated osteoporotic bone loss driven by myeloid-specific Wtap deficiency in vivo. This KLF9/WTAP/YTHDF2/m6A/CSF1R axis establishes a novel epigenetic circuit regulating bone resorption. Therapeutically, targeting this axis via AAV-mediated Wtap overexpression or pharmacological CSF1R inhibition with pexidartinib effectively ameliorates bone loss in osteoporotic mice. Our findings elucidate a previously unrecognized epitranscriptomic mechanism controlling osteoclastogenesis and highlight its therapeutic potential for pathological bone resorption.

PubMedAnti-cancer drugs2026-08-30

Estrogen-related receptor α promotes breast cancer cell migration and invasion by activating transforming growth factor β signaling.

Prusty Monica M, Muduli Kartik K, Pradhan Jagannath J, Samal Archana Priyadarshini AP et al.

Breast cancer is a major cause of cancer-related mortality among women, and many patients eventually experience recurrence and progression to metastasis, despite advances in treatment. Estrogen-related receptor α (ERRα), an orphan nuclear receptor, is frequently overexpressed in aggressive breast cancer subtypes and is associated with poor prognosis and an increased risk of recurrence. This study aimed to investigate the role of transforming growth factor β (TGFβ) signaling in ERRα-mediated epithelial-mesenchymal transition (EMT), migration, and invasion in breast cancer cells. ERRα expression was modulated in breast cancer cells using XCT790-mediated inhibition, shRNA-mediated knockdown, and overexpression. Cell viability, clonogenicity, migration, invasion, EMT marker expression, and matrix metalloproteinase (MMP) activity were evaluated. TGFβ1 secretion and Smad signaling were also evaluated. XCT790-mediated inhibition or shRNA-mediated silencing of ERRα significantly reduced cell viability, migration, invasion, and MMP secretion in breast cancer cell lines, whereas ERRα overexpression upregulated migration, invasion, and MMP levels. ERRα suppression also upregulated the epithelial marker ZO-1 and downregulated mesenchymal markers, such as vimentin and β-catenin. This effect was associated with a significant decrease in TGFβ secretion, downregulation of TGFβ-mediated Smad signaling, and reduced expression of its downstream target ANGPTL4. These findings indicate that ERRα promotes EMT, migration, and invasion in breast cancer by upregulating TGFβ secretion and its signaling, underscoring its potential as a therapeutic target.

PubMedNPJ breast cancer2026-08-30

Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations.

Schagerholm Stanev Caroline C, Robertson Stephanie S, Toosi Hosein H, Sifakis Emmanouil G EG et al.

The majority of breast cancer patients have tumors expressing estrogen receptor α (ER) and receive endocrine therapy. However, around one-third relapse in their disease, predominantly with retained ER expression. Molecular alterations are proposed to be contributors to the resistance mechanisms. Patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer with an ER-positive relapse < 5 years of ongoing endocrine therapy were retrospectively assessed. Extracted DNA was analyzed through panel sequencing, and RNA by microarray, from patients' primary (n = 58), and paired relapse tumors (n = 54), and tumor-free lymph nodes (DNA germline controls, n = 62). Several single-nucleotide variations and copy number variations showed nominal exploratory associations with worse overall survival. Copy number correlations with intrinsic subtypes and individual gene expression supported the findings. These results identify hypothesis-generating genomic and transcriptomic features, including potentially targetable alterations, in a clinically defined cohort of endocrine-resistant breast cancer patients.

PubMedGeneral and comparative endocrinology2026-08-30

Proteomic profiling of the aqueous extract from the antennal gland of the Pacific white shrimp, Litopenaeus vannamei.

Alvarado-Mesén Javier J, Umaña-Castro Rodolfo R, Fernández Julián J, Lomonte Bruno B et al.

The antennal gland (AnG) of decapod crustaceans has been proposed as a potential source of bioactive molecules involved in chemical communication; however, its protein composition remains largely unexplored. Here, we present the first reference proteomic map of the aqueous extract from the antennal gland of the Pacific white shrimp Litopenaeus vannamei. Protein extracts from immature and mature females were analyzed using an integrated workflow combining one-dimensional SDS-PAGE, reverse-phase high-performance liquid chromatography (RP-HPLC), and nanoLC-tandem mass spectrometry. Electrophoretic and chromatographic analyses revealed a high degree of qualitative similarity between reproductive stages. SDS-PAGE resolved six major protein bands (~227, 166, 77, 42, 35, and 17 kDa), most comprising multiple co-migrating proteins as revealed by LC-MS/MS. Hemocyanin was identified as the predominant protein and was detected across several electrophoretic bands. Additional proteins were associated with innate immunity, including β-1,3-glucan-binding protein and coagulable hemolymph protein; reproductive processes, including vitellogenin, spermatogonial stem-cell renewal factor, farnesoic acid O-methyltransferase, estrogen sulfotransferase, and prostaglandin reductase 1; as well as energy metabolism, protein homeostasis, cytoskeletal organization, and intracellular trafficking. Because several identified proteins are widely distributed or known hemolymph components, their detection cannot be assumed to reflect AnG-specific expression or function. Collectively, these findings establish a molecular reference for the L. vannamei AnG and reveal protein components associated with multiple physiological processes. This dataset provides a proteomic framework for future comparative and functional studies aimed at elucidating antennal gland physiology and experimentally evaluating the potential involvement of proteinaceous or peptide-based molecules in chemical communication in decapod crustaceans.

PubMedMolecular biology reports2026-08-29

Cyclofenil blocks the secretion of IL-1β by inhibiting assembly of the NLRP3 inflammasome independent of estrogen receptor.

Feng Jieqiong J, Yan Youyou Y, Liang Jiafeng J, Zhao Yanyan Y et al.

Cyclofenil is a modulator of estrogen receptor and is used clinically as an ovulation-inducing drug with antiviral activity. However, the mechanism by which cyclofenil works without estrogen receptor remains unknown. In this study, we screened for a small-molecule drug targeting the NLRP3 inflammasome and found that cyclofenil inhibited the secretion of IL-1β in a dose-dependent manner. Intriguingly, cyclofenil impedes activation of the NLRP3 inflammasome, independent of estrogen receptor, without interfering with the priming stage. Additionally, cyclofenil blocks ASC oligomerization and pyroptosis, preventing maturation of IL-1β and caspase-1. This study offers new evidence that cyclofenil is an anti-inflammatory drug and may be a novel clinical option for NLRP3 inflammasome-related diseases.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about estrogen